Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01657331 · ClinicalTrials.gov registry record · Phase 1
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
A Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT01657331 is a Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 65 participants.
The verdict
NCT01657331, a Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is a phase 1/2 multicenter study to assess the safety and effectiveness of brentuximab vedotin and bendamustine, when given together, in patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma (ALCL) that has either returned or did not respond to initial treatment(s). Patients will be accrued at Columbia University Medical Center (CUMC) and at two subsites in Canada.
Interventions
- DRUG Brentuximab Vedotin
- DRUG Bendamustine
- DRUG Neulasta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2012-07 |
| Est. Completion | 2018-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01657331
The ClinicalTrials.gov registry entry for NCT01657331 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Brentuximab Vedotin is the first listed.
NCT01657331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01657331 about?
NCT01657331 is a clinical study titled "Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)". This is a phase 1/2 multicenter study to assess the safety and effectiveness of brentuximab vedotin and bendamustine, when given together, in patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma (ALCL) that has either returned or did not respond to initial treatment(s). Patients will be ...
What is the current status of trial NCT01657331?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2012-07. Estimated completion is 2018-06.
What interventions are being tested in trial NCT01657331?
The interventions under investigation include: Brentuximab Vedotin (DRUG), Bendamustine (DRUG), Neulasta (DRUG).
Who is sponsoring clinical trial NCT01657331?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.